INTRODUCTION
Colorectal cancer (CRC) remains one of the most common and lethal malignancies worldwide, and is the second leading cause of cancer-related deaths in the USA. 1 At the time of initial diagnosis, a large majority of patients have already reached an advanced stage where tumour cell spreading has occurred, and approximately 50% of patients with CRC will die from the development of distant metastases. 2 3 Although progress in treatment options, such as development of novel chemotherapeutic drugs and technical advances in invasive treatment for metastatic lesion, has somewhat improved the prognosis of advanced patients with CRC, 4 5 there is still a clear need for prognostic biomarkers that can help identify high-risk patients who can benefit from intensive post-treatment surveillance protocols for early detection of recurrence.
The central dogma of gene expression is that genetic information flows in a unidirectional fashion of DNA-messenger RNA (mRNA)-proteins. 6 Therefore, the majority of previous research in molecular and cellular biology has focused on the protein-coding genes and their
Significance of this study
What is already known on this subject?
▸ Colorectal cancer (CRC) remains a leading cause of cancer mortality and is the second leading cause of cancer-related deaths in the USA. ▸ Small nucleolar RNA (snoRNAs) are one of the largest groups of single-stranded small non-coding RNAs, and emerging evidence highlights their role in the regulation of cell fate and oncogenesis in various cancers. In addition, recent studies suggest that these RNAs may have prognostic impact and biomarker potential in solid cancers.
What are the new findings?
▸ This study evaluated snoRNA expression using colorectal tissues from multiple independent tissue cohorts in a series of experimental assays and approaches. ▸ This study successfully demonstrated, for the first time, the clinical impact of snoRNA expression as a predictive biomarker of recurrence and poor prognosis in patients with CRC. ▸ We clearly demonstrate that high expression of SNORA42 significantly correlated with distant metastasis in CRC tissues, and SNORA42 expression status is an independent prognostic risk factor for predicting distant metastasis in patients with CRC. ▸ We used a series of cell culture experiments to uncover the oncogenic role of SNORA42 in CRC, followed by validation of these findings in an in vivo model.
transcripts, and mRNAs. However, in the past decade, noncoding RNAs (ncRNAs) have emerged as frontiers in gene regulation due to their important role in regulating various biological processes in various diseases, particularly cancer development. In this context, with the discovery of microRNAs (miRNAs) and their critical role in biological and physiological process in oncogenesis, [7] [8] [9] [10] other ncRNAs are now beginning to gather increased attention as potential regulators of tumorigenesis.
Small nucleolar RNAs (snoRNAs) are one of the largest groups of single-stranded small ncRNAs with 60-300 nucleotides in length 11 and are categorised into two main groups. Box C/D snoRNAs (SNORDs) serve as guides for the 2 0 -O-ribose methylation of rRNAs or small nuclear RNAs, whereas box H/ACA snoRNAs (SNORAs) are guides for isomerisation of uridine residues into pseudouridine. 12 Thus, in the past, snoRNAs were recognised for housekeeping functions due to their critical roles in rRNA maturation, while causing a relatively low impact on cellular homeostasis. However, recent emerging evidence has revealed a completely new and previously unrecognised role of snoRNAs in the control of cell fate and oncogenesis in various cancers. [13] [14] [15] [16] [17] In addition, recent studies have indicated potential prognostic impact and biomarker potential of snoRNA in solid cancers. 18 19 Recently, expression status of SNORD76, SNORD78, ACA11 and SNORA42 were reported to be upregulated in various cancerous tissues. [20] [21] [22] SNORD76 and SNORD78 are located at 1q25 locus, and are encoded within the intron of a long-coding RNA, growth arrest-specific transcript 5 gene (GAS5). Although increasing body of literature supports the functional role of GAS5 in cancer development, 13 14 23 24 increased expression of GAS5-related snoRNAs, such as SNORD76 and SNORD78, has also been suggested in non-small cell lung cancer (NSCLC) tissues. 20 In addition, this study also demonstrated that SNORD76 and SNORD78 levels were upregulated in serum of patients with NSCLC and suggested that these snoRNAs could be used as non-invasive diagnostic biomarkers in patients with NSCLC. Recently, Chu and colleagues revealed oncogenic function of another type of snoRNA, ACA11, which is encoded within introns 18-19 of the WHSC1 gene and demonstrated its function in binding to heterogeneous nuclear ribonucleoproteins rather than the proteins involved in ribosomal biogenesis in multiple myeloma. 22 Furthermore, another study demonstrated that SNORA42 was frequently overexpressed in NSCLC tissues and confirmed its oncogenic function through a series of in vitro and in vivo experiments. In addition, high expression of SNORA42 significantly correlated with poor prognosis in patients with NSCLC, suggesting it to be a potentially relevant diagnostic and therapeutic target in NSCLC. 21 In spite of the growing evidence supporting the functional role of snoRNAs in tumorigenesis and their potential as a biomarker, to the best of our knowledge, none of the previous studies have investigated the clinical significance and their functional role in CRC progression.
Previous work from our group has shown that several miRNAs are differentially expressed in CRC and can be used as biomarkers for diagnosis, prognosis and metastasis prediction in patients with CRC. [25] [26] [27] [28] [29] In this study, we systematically investigated the expression of specific snoRNAs using a three-phase study. In the first phase, we focused our attention on four snoRNAs that have previously been reported to be dysregulated in other human cancers. [20] [21] [22] We performed quantitative analyses for determining the expression of these snoRNAs in a subset of clinical specimens from patients with CRC to determine their expression pattern in cancers versus matched normal mucosa (NM). In the second phase, we performed clinical validation of snoRNA expression status using a large cohort of clinical materials. Furthermore, we focused on SNORA42 in an additional, independent cohort of CRC tissues to confirm its performance as a prognostic biomarker. In the final phase, we performed functional analysis by altering SNORA42 expression in colon cancer cell lines and undertook extensive in vitro and in vivo experiments to characterise its biological role in CRC progression.
MATERIALS AND METHODS Patients and sample collection
This study included examination of 274 tissue specimens including 250 formalin-fixed paraffin-embedded (FFPE) primary CRC (pCRC) tissues and 24 matched corresponding NM tissues from three different CRC patient cohorts that were enrolled at Mie University and Okayama University in Japan, as described in online supplementary table S1. Further information on patient demographics and clinicopathological characteristics is provided in the online supplementary material and methods.
SnoRNA expression by qRT-PCR and in situ hybridisation analysis
Total RNA were extracted from FFPE specimens using Total Nucleic Acid Isolation Kits for FFPE tissues (Ambion, Austin, TX, USA). Careful microdissection was performed on FFPE tissue slides to enrich for tumour cells. Expression of snoRNAs was analysed using Custom TaqMan small RNA assays (Applied Biosystems, Foster City, CA, USA), and the average expression levels of snoRNAs were normalised against miR-16. MiR-16 was chosen as the endogenous normaliser for quantitation of snoRNA expression based on the previous findings that miR-16 was one of the most suitable reference genes for relative quantification of small ncRNAs, as well as in line with previous publications demonstrating that miR-16 is a reliable normaliser for ncRNAs in tissue specimens. 25 28 30-32 For in situ hybridisation (ISH) analysis, 5-μm-thick FFPE tissue sections were hybridised with the SNORA42 probe (locked nucleic acid-modified and 5 0 -and 3 0 -digoxigenin-labelled oligonucleotide; Exiqon, Woburn, MA, USA), as described previously. 27 28 Positive (U6 snRNA, Exiqon) and negative controls (scrambled, Exiqon) were included in each hybridisation experiment. 27 28 32 
Cell lines
Human colon cancer cell lines Caco2, HCT116, HT29, LoVo, SW480 and SW620 were obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). These cell lines were tested and authenticated using a panel of genetic and epigenetic markers on a regular basis. All cell lines were maintained in Iscove's modified Dulbecco's medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum and antibiotics at 37°C in a 5% humidified CO 2 atmosphere.
Establishment of SNORA42 overexpressing cell lines SNORA42 was cloned as described previously. 21 A pCDH vector (System Biosciences, Mountain View, CA, USA) was used for ectopic overexpression of SNORA42. The pCDH vector encoding intact sequence of SNORA42 cDNA or empty vector as a control was infected into HEK293T cells together with pPACKH1 Packaging Plasmid mix (System Biosciences) for producing viral particles using Lipofectamine 2000 (Invitrogen). Further information is provided in the online supplementary material and methods.
Silencing of SNORA42 expression in CRC cell line SNORA42 expression was silenced in HCT116 cells using SNORA42 sgRNA CRISPR/Cas9 All-in-One Lentivector set (Human; Applied Biological Materials, Richmond, BC, Canada), which contained SNORA42-specific target sequences and scrambled sequences, according to the manufacturer's instruction. Further information is provided in the online supplementary material and methods.
Cell proliferation and colony formation assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma, St. Louis, MO, USA) was used to determine the degree of cell proliferation as described previously. 33 For colony formation assay, the number of colonies with >50 cells was counted after seeding of colon cancer cell lines following the manufacturer's instruction. Further information is provided in the online supplementary material and methods.
Cell invasion, migration and anoikis assay
Invasion and migration assays were performed using Boyden chambers (Corning, Corning, NY, USA) using 8 mm pore size membrane with Matrigel (for invasion assay) or without Matrigel (for migration assay). Anoikis assay was performed as described previously. 34 All experiments were conducted as three independent experiments. Further information is provided in the online supplementary material and methods.
In vivo studies
Male athymic nude mice were obtained from Harlan Laboratories (Houston, TX, USA) at 5 weeks of age and kept under controlled conditions (12 h light and dark cycles). The animal protocol was approved by the Institutional Animal Care and Use Committee of the Baylor Research Institute. We The y-axis represents relative expression of four snoRNA, and data were normalised to miR-16 expression. Statistical analysis was performed using Mann-Whitney U tests. All statistical tests were two-sided. **p<0.01; ***p<0.001. generated xenograft tumours using SW480 cell line stably overexpressing SNORA42 or its controls. These cancer cells were suspended in phosphate-buffered saline and Matrigel (Corning; 1:1 ratio) and 3×10 6 cells were subcutaneously injected into the abdominal flanks of each mice. Matrigel was used to improve the attachment and differentiation of both SNORA42 stably overexpressed cells and control cells in athymic nude mice. Nine mice were used in each group, and subcutaneous tumours were monitored for 28 days following injection. Further information is provided in online supplementary material and methods.
Statistical analysis
Results were expressed as means±SE, and all statistical analyses were performed using Medcalc V.12.3.0 (Broekstraat 52, 9030; Mariakerke, Belgium). Further information is provided in the online supplementary material and methods.
RESULTS

Overexpression of snoRNAs in CRC during the screening phase
In the screening step of this study, expression levels of four snoRNAs (SNORD76, SNORD78, ACA11 and SNORA42) were examined in a subset of 16 CRCs and paired adjacent NM by quantitative real-time PCR. The expression levels of all for snoRNAs were significantly higher in CRC tissues compared with matched NM tissue specimens (SNORD76, p<0.01; SNORD78, p<0.01; ACA11, p<0.01; SNORA42, p<0.01; figure 1A ).
High SNORA42 expression was associated with distant metastasis and poor outcome in patients with CRC during the clinical validation phase Next, we analysed the expression patterns for all four snoRNAs with various clinicopathological factors to determine whether their expression status has any prognostic significance in patients with CRC by analysing an independent, large cohort of patients with CRC (see online supplementary table S1). In line with our screening phase results, the expression levels of all snoRNAs in CRC tissues were significantly upregulated in tumour versus NM tissues in the clinical evaluation cohort (SNORD76, p<0.001; SNORD78, p<0.001; ACA11, p<0.001; SNORA42, p<0.01; figure 1B) . Receiver operating characteristic (ROC) curves were used to evaluate the sensitivity and specificity of each snoRNA expression in distinguishing CRC from normal tissues. Notably, expression of all snoRNAs displayed considerable predictive significance, with an area under the curve values of 0.79 (95% CI 0.73 to 0.82), 0.78 (95% CI 0.72 to 0.84), 0.88 (95% CI 0.83 to 0.92) and 0.75 (95% CI 0.69 to 0.81), respectively (see online supplementary figure S1).
Further, to perform the time-to-event analysis in order to evaluate the prognostic impact of these snoRNAs, median value of each snoRNA expression in all patients and curatively resected patients with stage I/II/III disease were used as cut-off thresholds for analysing prognostic impact of overall survival (OS) and disease-free survival (DFS), respectively. Patients with CRC with expression values higher than the median for each snoRNA were assigned to a high-expression group and the others to a low-expression group. Although expression status of three snoRNAs (SNORD76, SNORD78 and ACA11) did not significantly correlate with survival or any other clinicopathological factors, high SNORA42 expression associated with venous invasion, lymphatic invasion, distant metastasis, the Union for International Cancer Control classification (table 1, see online  supplementary table S2) figure 2A,B) . Multivariate Cox's regression analysis showed high SNORA42 expression was an independent prognostic factor for OS (HR 2.11, 95% CI 1.12 to 3.98, p=0.021) and DFS (HR 3.17, 95% CI 1.32 to 7.65, p=0.011) in patients with CRC (tables 2 and 3). Furthermore, multivariate logistic regression analysis revealed that high expression of SNORA42 was also an independent predictor of distant metastasis in patients with CRC (OR 2.66, 95% CI 1.14 to 6.21, p=0.023, table 4).
Prognostic impact of SNORA42 expression status in patients with CRC during the performance evaluation phase To further confirm the prognostic impact of SNORA42 expression in patients with CRC, we validated our results in an additional independent CRC cohort. Intriguingly, consistent with the survival outcomes in the clinical validation cohort, high SNORA42 expression was associated with poor prognosis with regard to OS for performance evaluation cohort ( p=0.026, log-rank test, figure 2C ) and total cohort (p=0.002, log-rank test, figure 2D ). Furthermore, multivariate Cox's regression analysis revealed that high SNORA42 expression was an independent predictor for poor prognosis in the performance evaluation cohort, as well as total cohort (HR 3.00, 95% CI 1.10 to 8.19, p=0.033; HR 2.5, 95% CI 1.51 to 4.14, p=0.0004, respectively, tables 5 and 6). The OS rate in patients with CRC (n=96) with high-SNORA42 expression in tumour tissue was significantly lower than that for those with low-SNORA42 expression (cut-off threshold was median value in this cohort; p=0.018; log-rank test). (B) Disease-free survival analyses based on SNORA42 expression status in CRC tissue cohort (cut-off threshold was median value in patients with stage I-III CRC; p=0.029; log-rank test). (C and D) OS analysis based on SNORA42 expression status in performance evaluation cohort (C) (n=50) and total cohort (D) (n=250) (cut-off threshold was median value in each cohort; p=0.026 and 0.002, respectively; log-rank test). All statistical tests were two-sided.
SNORA42 expression status identified high-risk patients with stage II CRC
Next, to determine the clinical significance of SNORA42 expression as a predictive biomarker of recurrence and prognosis in patients with stage II CRC, we evaluated survival outcomes in stage II patients subdivided on the basis of tissue SNORA42 expression (shown in online supplementary figure S2a-c). Elevated SNORA42 expression was associated with poor OS and DFS in patients belonging to the clinical validation cohort ( p=0.048 and 0.049, respectively, log-rank test). Furthermore, high expression status of SNORA42 was significantly associated with poor prognosis in patients with stage II disease in the total cohort ( p=0.039, log-rank test). Collectively, our data suggest that SNORA42 expression could identify high-risk patients with stage II CRC.
SNORA42 were highly expressed in cancer cells compared with cancer stroma or corresponding NM
To further confirm the pathological expression pattern of SNORA42 in clinical specimens, ISH staining was performed on 10 pCRC tissues and corresponding adjacent NM from the clinical validation cohort. The ISH experiments revealed nuclear staining for SNORA42 in CRC cells, an observation that is consistent with previous reports in NSCLC. 21 Furthermore, SNORA42 expression was upregulated in the pCRC cells compared with the matched NM, confirming our qRT-PCR results for its expression in pCRC and adjacent NM tissues (see online supplementary figure S3). Based on these results, SNORA42 was overexpressed in CRC cells compared with NM, and its expression significantly correlated with disease progression in patients with CRC. Therefore, we decided to focus the rest of the study on SNORA42 for further assessment of its biological function in colorectal neoplasia.
Overexpression of SNORA42 results in increased cell proliferation, tumorigenicity, migration, invasion and anoikis resistance in colon cancer cells
To investigate whether SNORA42 alters the biological characteristics of colon cancer cells, we first assessed expression levels of SNORA42 in a panel of colon cancer cell lines (Caco2, HCT116, HT29, LoVo, SW480 and SW620) by real-time PCR. Interestingly, the expression of SNORA42 was upregulated in metastatic cell line (SW620) compared with pCRC cell line (SW480) derived from the same patient. We selected Caco2 and SW480 cell lines for overexpression studies since both cell lines showed lowest SNORA42 expression ( figure 3A) . The pCDH-SNORA42 and pCDH-controls were transfected into these cell lines, which facilitated significant overexpression of SNORA42 in these cells ( figure 3B) .
In order to determine whether ectopic expression of SNORA42 resulted in enhanced cell proliferation in human cancer cell lines, we performed MTT assays using transfected cell lines. Cell proliferation was significantly increased in both SNORA42 overexpressing cell lines compared with control cell lines ( figure 3C) . Next, to examine the colony-forming ability of single cells overexpressing SNORA42, we performed colony formation assays. Both Caco2 and SW480 cells expressing pCDH-SNORA42 demonstrated significantly higher number of colonies compared with pCDH-control cell lines ( figure 3D ).
To determine whether ectopic expression of SNORA42 altered cell migration and invasion, we performed in vitro migration and invasion assays. As shown in figure 3E , SNORA42 overexpressing colon cancer cell lines showed significantly enhanced invasive and migratory potential compared with pCDH-control cells.
Anoikis is a unique form of apoptosis that is induced by detachment of cells from the extracellular matrix. 35 36 Resistance to anoikis is recognised as one of the oncogenic hallmarks contributing to cancer metastasis. [37] [38] [39] Considering that our clinical data revealed SNORA42 overexpression as an independent risk factor for distant metastasis, we hypothesised that SNORA42 enhances resistance to anoikis in colon cancer cells. To further confirm whether ectopic expression of SNORA42 increases anoikis resistance, anchorage independent cell viability was assessed after cells were incubated in an ultra-low attachment plate. After induction of anoikis, SNORA42 overexpressing Caco2 and SW480 cells exhibited an increase in the number of viable cells compared with the control cells ( figure 3F ).
Inhibition of SNORA42 suppresses cell proliferation, tumorigenicity, invasion and anoikis resistance in colon cancer cell
To confirm the oncogenic function of SNORA42, we next performed SNORA42 gene-silencing using CRISPR/Cas9 system. We used lentiviral vectors to infect HCT116 cells with two different sequences of SNORA42 sgRNA CRISPR/Cas9 and downregulated SNORA42 expression (see online supplementary figure S4a). Both cell proliferation and colony formation capacity were significantly suppressed in both SNORA42 knock- down cell lines compared with the controls (see online supplementary figure S4b, c). Next, we assessed whether inhibition of SNORA42 suppresses invasion capacity and anoikis resistance in colon cancer cells. Invasion assay showed that knock-down of SNORA42 inhibited the invasive ability in colon cancer cell, while anoikis assay showed suppression of SNORA42 induced anoikis in both SNORA42 knock-down cell lines. Collectively, these results indicate that SNORA42 is involved in CRC pathogenesis by promoting cell growth, colonogenic survival and enhancing invasion, migration and anoikis resistance. (I) SNORA42 expression levels in xenograft tumours, which were treated with pCDH-SNORA42 or pCDH-control. Statistical analysis was performed using one-way analysis of variance and Mann-Whitney U tests appropriately. All statistical tests were two-sided. *p<0.05, **p<0.01, ***p<0.001.
High SNORA42 expression results in enhanced CRC growth in an animal model
To assess whether ectopic expression of SNORA42 promotes tumorigenicity in vivo, we subcutaneously injected SW480 cells stably overexpressing SNORA42 or control (3×10 6 cells per mouse) into nude mice. During the initial 13 days post injection, no significant difference in tumour size was observed between two groups. However, mice injected with SNORA42-expressing cells appear to accelerate tumour growth around 16 days post-injection compared with the control group (figure 3G). Tumour size and weight were significantly higher for SNORA42-expressing cells than those of control animals (figure 3H, see online supplementary table S3) at 28 days after injection, and overexpression of SNORA42 was maintained in the tumour tissues compared with control cells at the end of experiments (figure 3I). Collectively, these results clearly demonstrate that high SNORA42 expression enhanced tumour growth in vivo, which is consistent with our in vitro and clinical findings.
DISCUSSION
Growing evidence supports the role of ncRNAs in regulation of oncogenesis in different cancers. [40] [41] [42] In addition to their significant role in the pathogenesis of CRC, more recent discovery of miRNAs as potential robust biomarkers has paved the way for exploitation of other types of small ncRNAs-a concept that has revolutionised the field of ncRNA biomarkers for the early detection, predicting recurrence and prognostication in CRC. In contrast to relatively well-characterised role of miRNAs, little is known about the biological significance of snoRNAs. Furthermore, the association between snoRNA expression and their clinical impact as biomarkers for CRC has not been undertaken.
In this study, we systematically investigated potential role of four oncogenic snoRNAs and provided first evidence of snoRNA dysregulation in CRC. We made several important discoveries during the course of this investigation. First, expression of all four snoRNAs was significantly upregulated in CRCs compared with NM. ROC analyses revealed that expression of these snoRNAs considerably discriminated cancer tissues from NM. Second, we identified that high expression of SNORA42, in particular, correlated significantly with poor OS and DFS in patients with CRC. In addition, SNORA42 expression in primary tissues emerged as an independent prognostic risk factor for distant metastasis in patients with CRC. Third, we validated prognostic impact of SNORA42 expression in another independent cohort of patients with CRC. Fourth, we showed that high expression of SNORA42 could identify patients that are at high risk for tumour recurrence, particularly in patients with stage II CRC. Finally, altered expression of SNORA42 changed not only invasive and migratory capacity of Figure 3 Continued CRC cells but also cell proliferation, tumorigenicity, and anoikis resistance, as evidenced from a series of in vitro and in vivo experiments.
One of the major findings of our study is that expression status of all four snoRNAs was significantly higher in cancerous tissues compared with NM from CRC specimens analysed during the screening and validation phases. Since there were no studies on the role of snoRNAs in CRC, we purposely focused our study on deciphering the role of these previously reported snoRNAs to determine whether they also play a role in CRC pathogenesis. Nonetheless, our ROC analysis for the expression levels of all 4 snoRNAs demonstrated that these were consistently upregulated in cancer versus normal tissues, suggesting their potential use as tissue-based diagnostic biomarkers in CRC patients.
Another major finding of our study is the clinical impact of snoRNA expression levels in CRC patients. Our results in the clinical validation cohort showed that elevated expression of SNORA42 was a potential predictor for recurrence and poor prognosis in CRC patients. Interestingly, logistic regression analysis indicated that high SNORA42 expression in cancer tissues was an independent risk factor for predicting distant metastasis in CRC patients. These results were successfully validated in CRC specimens from an independent cohort, suggesting that SNORA42 expression could be used as a prognostic biomarker as it is intimately involved in disease progression in CRC. In line with findings, our results illustrated that high expression of SNORA42 correlated significantly with poor prognosis of DFS and OS in patients with stage II CRC. Currently, one of the most clinically relevant needs is lack of availability of adequate predictive biomarkers that can identify patients that are at high risk for developing tumour recurrence, especially in patients with stage II CRC. Even though the majority of these patients are cured by surgery alone, a significant proportion of patients with stage II CRC develop relapse and subsequently die from disease progression. Furthermore, the effect of treating all patients with stage II CRC with adjuvant chemotherapy remains controversial. [43] [44] [45] Therefore, identification of such high-risk patients with CRC using molecular biomarkers such as SNORA42 expression will allow use of adjuvant chemotherapy after surgery only in a select subgroup of high-risk patients to improve their prognosis.
To further understand the biological function of SNORA42 in CRC progression, we investigated the malignant features of SNORA42 in colon cancer cell lines, Caco2 and SW480, using pCDH-SNORA42 infection. Recent studies highlighted the oncogenic role of SNORA42 in lung tumorigenesis. 21 46 Consistent with these previous data, 21 we demonstrated that ectopic expression of SNORA42 enhanced cell proliferation and tumorigenicity in cultured cells and in an animal model of CRC. Our data showed that ectopic expression of SNORA42 exerted distinct oncogenic functions such as increased invasion, migration and anoikis resistance in colon cancer cell lines, while inhibition of SNORA42 by CRISPR-Cas9 further supported this paradigm. According to the current knowledge, formation of metastasis occurs in multiple steps. In the metastatic process, primary tumour invades into the serosa from the intraluminal epithelial side, followed by cancer cells detachment from the primary tumour and extravasation into the circulation. These cancer cells thereafter adhere to the microvascular endothelium and proliferate to distant organs. 47 48 In summary, this study provides novel evidences for the clinical and biological significance of snoRNAs in CRC. Our results demonstrate the clinical usefulness of SNORA42 as potential of diagnostic and predictive biomarker for risk stratification in patients with CRC. Furthermore, our results from a series of in vitro and in vivo experiments supported a mechanistic role of SNORA42 in the CRC tumorigenesis. In this study, we successfully revealed the role of SNORA42 as a clinically promising biomarker, and further studies including a broader, unbiased genome-wide analysis in future might lead to the identification of other, even more significant snoRNAs in CRC. We conclude that quantification of SNORA42 expression in primary tumours may serve as a clinically useful diagnostic and prognostic biomarker, and potentially as a therapeutic target in colorectal cancer.
